Do you consider MSI testing for nonserous ovarian cancer?

I do, but with the understanding that PD1/PDL1 expression, MSI/MMR is less well documented than in high grade serous cancers. Meagher et al has a nice article in Gyn Oncol 2018 looking at molecular profiling in 333 mucinous lesions. Common mutations noted were KRAS (60%), TP53 (38%), and HER2 in up to 13%. Trametinib may be an option for patients with particular KRAS mutations, and certainly trastuzumab may be an option for those with HER2 overexpression.

The goal is certainly to identify action...